Belantamab mafodotin
Blenrep · Antibody-drug conjugate (BCMA/MMAF)
Myeloma ADC; renal data emerging.
Sprycel · DASA
BCR-ABL TKI · approved 2006 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A second-generation BCR-ABL TKI with a distinctive signal of proteinuria and nephrotic-range glomerular injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Dasatinib causes significantly more albuminuria than other TKIs. In a pharmacokinetic cohort, dasatinib users had higher urine albumin-creatinine ratios and about 10% showed severely increased albuminuria (UACR >300 mg/g) versus none on other TKIs, with the degree of proteinuria correlating with plasma exposure. Nephrotic-range proteinuria with biopsy-proven glomerular injury (FSGS, podocyte foot-process effacement, endothelial injury) is reported in cases.Source: Adegbite et al., Clin J Am Soc Nephrol 2023
Proteinuria appears within weeks to months and increases with treatment duration and exposure.
Distilled from: “Proteinuria can appear within weeks to months and increases with treatment duration and exposure.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Potent second-generation inhibitor of BCR-ABL1 and SRC-family kinases (LCK, FYN, YES, SRC), with broader kinase coverage than imatinib and activity against most non-T315I resistance mutations. Used in chronic myeloid leukemia and Ph+ ALL.
Glomerulus
Filtration barrier (podocytes + endothelium)
Class-level context for the major non-renal toxicities of the BCR-ABL TKI class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 32,694 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
3,005 of 32,694 reports
Reported with hospitalization
7,228 of 32,694 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2,456 of the 32,694 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Dasatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Blenrep · Antibody-drug conjugate (BCMA/MMAF)
Myeloma ADC; renal data emerging.
Aredia · Bisphosphonate
Collapsing FSGS — first drug ever linked.
Intron A · Cytokine
Collapsing FSGS in APOL1 carriers.
Fruzaqla · VEGFR TKI
2023 colorectal VEGFR-TKI; hypertension and proteinuria, class effect.
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
Cabometyx · VEGFR/MET TKI
Hypertension and proteinuria; nephrotic case reports.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Dasatinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Dasatinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 48 clinical records among all 65 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.